Targeting C2CD2L for Drug Development (G9854)

Target Name: C2CD2L

NCBI ID: G9854

C2CD2L

Targeting C2CD2L for Drug Development

C2CD2L (Phospholipid transfer protein C2CD2L) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and blood vessels. It is a member of the C2 subfamily of phospholipid transfer proteins (PTP), which are a family of transmembrane proteins that play a crucial role in lipid metabolism.

C2CD2L is characterized by its unique structure, which consists of a long N-terminus, a transmembrane region, and a C-terminus. The N-terminus of C2CD2L contains a conserved region that is involved in protein-protein interactions, while the transmembrane region is made up of a variety of different lipid-binding domains. The C-terminus of C2CD2L contains a carbohydrate that is involved in its interactions with other proteins, such as integrins and adhesion molecules.

One of the key functions of C2CD2L is its role in lipid metabolism. It is a phospholipid transfer protein, which means that it can transfer phospholipids between different types of lipids. This is important for maintaining the integrity of cell membranes and for the proper functioning of various biological processes.

In addition to its role in lipid metabolism, C2CD2L is also involved in the regulation of cellular signaling pathways. It has been shown to play a role in the regulation of cell adhesion, as well as the migration and invasion of cancer cells. It is also involved in the regulation of inflammation, as it has been shown to play a role in the recruitment of immune cells to sites of infection.

Despite its involvement in a wide range of biological processes, C2CD2L is not well understood, and there is a lack of research on its function. This is why it is an attractive target for drug development, as researchers believe that modifying its activity could lead to the development of new treatments for a variety of diseases.

One potential approach to targeting C2CD2L is through the use of small molecules, such as drugs that can modulate its activity. Researchers have identified a number of potential small molecules that have been shown to interact with C2CD2L, and these molecules have the potential to be used as lead compounds for drug development.

Another approach to targeting C2CD2L is through the use of antibodies that can specifically recognize and target its transmembrane domain. Researchers have generated antibodies that are capable of recognizing and binding to C2CD2L, and these antibodies have the potential to be used as a diagnostic tool or as a therapeutic agent.

In conclusion, C2CD2L is a protein that is involved in a wide range of biological processes, including lipid metabolism and cellular signaling pathways. Despite its importance, there is a lack of research on its function, and it is an attractive target for drug development. The development of new treatments for a variety of diseases could be greatly improved by modifying C2CD2L's activity.

Protein Name: C2CD2 Like

Functions: Lipid-binding protein that transports phosphatidylinositol, the precursor of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2), from its site of synthesis in the endoplasmic reticulum to the cell membrane (PubMed:28209843). It thereby maintains the pool of cell membrane phosphoinositides, which are degraded during phospholipase C (PLC) signaling (PubMed:28209843). Plays a key role in the coordination of Ca(2+) and phosphoinositide signaling: localizes to sites of contact between the endoplasmic reticulum and the cell membrane, where it tethers the two bilayers (PubMed:28209843). In response to elevation of cytosolic Ca(2+), it is phosphorylated at its C-terminus and dissociates from the cell membrane, abolishing phosphatidylinositol transport to the cell membrane (PubMed:28209843). Positively regulates insulin secretion in response to glucose: phosphatidylinositol transfer to the cell membrane allows replenishment of PI(4,5)P2 pools and calcium channel opening, priming a new population of insulin granules (PubMed:28209843)

The "C2CD2L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C2CD2L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets